Prasad Namrata, Kobayashi Miwako, Collins Jennifer P, Rubis Amy B, Derado Gordana, Delahoy Miranda J, Payne Daniel C, McGee Lesley, Chochua Sopio, Marjuki Henju, McNamara Lucy A, Fox LeAnne M, Reingold Arthur, Barnes Megan, Petit Susan, Farley Monica M, Harrison Lee H, Lynfield Ruth, Houston Jessica, Anderson Bridget J, Thomas Ann, Talbot Keipp H, Schaffner William, Cohen Adam L, Schrag Stephanie J, Arvay Melissa
Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Lancet Reg Health Am. 2025 May 12;47:101120. doi: 10.1016/j.lana.2025.101120. eCollection 2025 Jul.
Bacterial meningitis is a severe syndrome with dynamic epidemiology, but assessments of current trends are limited. We aimed to describe changing epidemiologic patterns among common bacterial causes of meningitis in the United States.
We analyzed data on bacterial meningitis cases caused by , group B (GBS), , and in 10 U.S. surveillance sites. We compared incidence (cases per 100,000) across four epidemiologic periods: 2008-2009, 2010-2019, 2020-2021, and 2022-2023.
We identified 5,032 bacterial meningitis cases; among those with outcome data, 11% (573/5028) died. was the dominant pathogen (59% [2922/5032]) throughout. However, GBS predominated among infants aged 0-2 months (85% [660/775]), the age group with the highest incidence. Between 2008-2009 and 2010-2019, overall bacterial meningitis incidence declined from 1.3 to 1.1, driven by decreases in meningitis caused by serotypes contained in the 13-valent pneumococcal conjugate vaccine (PCV13) and meningitis. Meningitis caused by non-b strains increased during this period. During 2020-2021, incidence declined to 0.7, driven by decreases in and meningitis, regardless of organism subtype. During 2022-2023, incidence increased to 1.0, driven by increases in and meningitis. Case fatality ratios remained stable throughout.
Bacterial meningitis incidence rates have declined since 2008, with a notable low during 2020-2021, followed by a resurgence during 2022-2023. Case fatality remains high. Strategies that provide effective and broader pneumococcal and serotype protection and prevent infant GBS meningitis could reduce residual meningitis burden.
U.S. Centers for Disease Control and Prevention.
细菌性脑膜炎是一种具有动态流行病学特征的严重综合征，但对当前趋势的评估有限。我们旨在描述美国常见细菌性脑膜炎病因的流行病学模式变化。
我们分析了美国10个监测点由肺炎链球菌、B族链球菌（GBS）、脑膜炎奈瑟菌和流感嗜血杆菌引起的细菌性脑膜炎病例数据。我们比较了四个流行病学时期（2008 - 2009年、2010 - 2019年、2020 - 2021年和2022 - 2023年）的发病率（每10万人中的病例数）。
我们共识别出5032例细菌性脑膜炎病例；在有结局数据的病例中，11%（573/5028）死亡。肺炎链球菌在整个期间都是主要病原体（59%[2922/5032]）。然而，GBS在0至2个月大的婴儿中占主导（85%[660/775]），该年龄组发病率最高。在2008 - 2009年至2010 - 2019年期间，总体细菌性脑膜炎发病率从1.3降至1.1，这是由13价肺炎球菌结合疫苗（PCV13）所含血清型引起的肺炎链球菌脑膜炎和流感嗜血杆菌脑膜炎发病率下降所致。在此期间，非b型菌株引起的脑膜炎有所增加。在2020 - 2021年期间，发病率降至0.7，这是由肺炎链球菌和脑膜炎奈瑟菌脑膜炎发病率下降所致，无论病原体亚型如何。在2022 - 2023年期间，发病率升至1.0，这是由肺炎链球菌和流感嗜血杆菌脑膜炎发病率增加所致。病死率在整个期间保持稳定。
自2008年以来，细菌性脑膜炎发病率有所下降，在2020 - 2021年期间显著降低，随后在2022 - 2023年出现回升。病死率仍然很高。提供有效且更广泛的肺炎球菌和流感嗜血杆菌血清型保护以及预防婴儿GBS脑膜炎的策略可能会减轻残留的脑膜炎负担。
美国疾病控制与预防中心。
